陈远征 陈昱岐 白南

    [摘要]婴幼儿血管瘤是最常见的儿童体表软组织良性肿瘤，发病率高、危害大，早期快速增生会造成严重的外观畸形及器官发育障碍。普萘洛尔已经成为治疗婴幼儿血管瘤的一线药物，但是在临床应用研究中诸多方面存在差异，甚至是争议。为了促进其合理应用及明确需要进一步研究方向，本文就普萘洛尔治疗婴幼儿血管瘤的治疗剂量、给药次数、药物的不良反应及影响血管瘤复发的因素等内容进行综述。

    [关键词]婴幼儿血管瘤；普萘洛尔；治疗剂量；给药次数；不良反应；复发

    [中图分类号]R732.2? ? [文献标志码]A? ? [文章編号]1008-6455(2023)11-0189-05

    New Progress in Clinical Application of Oral Propranolol in the Treatment of Infantile Hemangioma

    CHEN Yuanzheng1，2，CHEN Yuqi3，BAI Nan4

    (1.Department of Burns and Plastic Surgery，Emergency General Hospital of the Ministry of Emergency Management，Beijing 100028，China; 2.Department of Burn and Plastic Surgery，Linyi People's Hospital，Linyi 276000，Shandong，China; 3.Jinan Foreign Language School，Jinan 250108，Shandong，China; 4.Department of Aesthetic Plastic Surgery，Linyi People's Hospital，Linyi 276000，Shandong，China)

    Abstract： Infantile hemangioma is the most common benign tumor of soft tissue in children. It has a high incidence rate and great harm. Early rapid proliferation can cause serious appearance deformity and organ development disorders. Propranolol has become the first-line drug for the treatment of infantile hemangioma ......